Important distinctions
Brand-name vs compounded GLP-1
What you should know about the differences. Compounded GLP-1 medications have become widely discussed as an alternative to brand-name products. This page presents factual information about the differences. This is not a recommendation for either option — consult your healthcare provider.
- Compared
- FDA-approved brands · Compounded versions
- Sources
- FDA communications and labels
Brand-name GLP-1: FDA-approved products
Brand-name GLP-1 medications are FDA-approved finished products manufactured by pharmaceutical companies under strict regulatory oversight. These include Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Saxenda.Each has undergone rigorous clinical trials, manufacturing inspections, and regulatory review before receiving FDA approval. They are produced in FDA-inspected facilities following current Good Manufacturing Practice (cGMP) standards.
Compounded GLP-1: pharmacy-prepared products
Compounded GLP-1 medications are prepared by compounding pharmacies, which mix active ingredients to fill specific prescriptions. These are not FDA-approved finished products.Compounding pharmacies are regulated primarily by state pharmacy boards. While compounding is a legitimate pharmaceutical practice, compounded products do not undergo the same FDA review process as brand-name medications.
What the FDA has said
Not FDA-approved products
The FDA has stated that compounded semaglutide and tirzepatide products are not FDA-approved. This means they have not undergone the agency's review for safety, efficacy, and quality that brand-name products receive.
Safety and quality concerns
The FDA has raised concerns about the safety, sterility, and potency of some compounded GLP-1 products. The agency has reported adverse event reports associated with compounded semaglutide, including some involving products that contained salt forms of semaglutide not used in approved products.
Shortage-related compounding
Under federal law, compounding pharmacies can prepare copies of commercially available drugs when those drugs are on the FDA's drug shortage list. As semaglutide and tirzepatide shortages have eased, the FDA has been tightening restrictions on compounding of these medications. The regulatory landscape continues to evolve.
FDA resources
The FDA maintains updated information about compounded semaglutide and tirzepatide on its website at FDA.gov. Patients are encouraged to review FDA communications and discuss them with their healthcare provider.
Key differences
A factual comparison of brand-name and compounded GLP-1 medications.
| Factor | Brand-name | Compounded |
|---|---|---|
| FDA approval | Yes — fully approved | No — not FDA-approved |
| Manufacturing standards | FDA cGMP (current Good Manufacturing Practice) | State pharmacy board oversight |
| Clinical trial data | Extensive published data | None for the specific compound |
| Cost | Higher list price | Often significantly lower |
| Insurance coverage | May be covered (varies by plan) | Rarely covered |
| Supply consistency | Manufacturer supply chain | Individual compounding pharmacy |
| Delivery devices | Proprietary pre-filled pens | Standard syringes or vials |
| Regulatory oversight | FDA | State pharmacy boards |
What to consider
Four key factors to discuss with your healthcare provider.
Regulatory oversight
Brand-name GLP-1 medications are manufactured under FDA oversight with cGMP standards. Compounded versions are regulated by state pharmacy boards, which have varying levels of oversight and enforcement.
Clinical evidence
FDA-approved products have extensive published clinical trial data supporting their safety and efficacy. Compounded versions of these drugs do not have their own clinical trial data, though they may contain the same active ingredient.
Cost factors
Compounded GLP-1 medications are typically significantly less expensive than brand-name products. However, insurance rarely covers compounded versions, while brand-name products may have insurance coverage and manufacturer savings programs.
Supply consistency
Brand-name products come from established pharmaceutical supply chains, though they have experienced shortages. Compounded products depend on individual pharmacies, which may have varying supply and quality practices.
Talk to your healthcare provider
This page presents factual information, not a recommendation. Your healthcare provider can discuss the benefits and considerations of each option based on your individual health situation, insurance coverage, and treatment goals.
Track any GLP-1 medication, free.
Dose AI tracks your injections, symptoms, weight, and nutrition regardless of which GLP-1 medication you use.
4.7 · 994 App Store ratings · 55,000+ downloads · Featured by Apple
Questions people ask
Is compounded semaglutide the same as Ozempic?
No. While compounded semaglutide may contain the same active ingredient, it is not the same as Ozempic or Wegovy. FDA-approved brand-name products undergo extensive manufacturing controls, clinical testing, and regulatory review that compounded versions do not. The FDA has stated that compounded semaglutide products are not FDA-approved finished products.
Is compounded GLP-1 safe?
The FDA has expressed concerns about the safety, sterility, and potency of some compounded GLP-1 products. Safety depends on the specific compounding pharmacy, its practices, and regulatory compliance. Some compounding pharmacies maintain high standards, while the FDA has identified quality issues at others. Discuss any concerns with your healthcare provider.
Why is compounded semaglutide cheaper?
Compounded medications are typically less expensive because they do not involve the costs of FDA clinical trials, brand-name marketing, or proprietary delivery devices. However, lower cost also reflects the absence of the same level of regulatory oversight, clinical data, and manufacturing standards that FDA-approved products require.
Can I switch from compounded to brand-name GLP-1?
Any medication change should be managed by your prescribing healthcare provider. Dosing, formulation, concentration, and potency may differ between compounded and brand-name versions. Your doctor can help plan a safe transition if appropriate.
What has the FDA said about compounded GLP-1?
The FDA has issued multiple communications regarding compounded semaglutide and tirzepatide. The agency has stated that compounded versions are not FDA-approved, raised concerns about safety and quality, reported adverse events, and has been restricting compounding as drug shortages ease. Updated information is available at FDA.gov.
Medical disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your healthcare provider before making any decisions about your health or medications.